Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer.
- VernacularTitle:厄罗替尼单药治疗晚期非小细胞肺癌的疗效和安全性分析
- Author:
Meng-zhao WANG
1
;
Xiao-tong ZHANG
;
Xin-yong ZHANG
;
Li ZHANG
;
Wei ZHONG
;
Li-yan XU
;
Long-yun LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Antineoplastic Agents; adverse effects; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; Chi-Square Distribution; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; drug therapy; Male; Middle Aged; Multivariate Analysis; Quinazolines; adverse effects; therapeutic use; Regression Analysis; Retrospective Studies; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2010;32(2):151-156
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the efficacy and safety of erlotinib monotherapy for advanced non-small cell lung cancer (NSCLC).
METHODSTotally 50 patients with advanced NSCLC received oral erlotinib 150 mg/d treatment, and tumor specimen in 19 patients were collected for epidermal growth factor receptor (EGFR) gene mutation tests. Median survival (MS) was calculated using the Kaplan-Meier method.
RESULTSThe most common adverse events (AEs) were skin rash (96%) and diarrhea (32%). The overall survival (OS) of all patients was 21.8 months 95% confidential interval (CI): 17.1-26.4 months and the median progression-free survival (PFS) of all patients was 7.0 months (95% CI: 3.9-10.1 months). EGFR mutation analysis showed gene mutation in 8 cases and wild type in 11 cases. The objective response rate in patients with or without EGFR gene mutations were 62.5% and 9.1%, respectively (chi(2)=6.631, P=0.036). PFS in patients with or without EGFR gene mutations were 16.330 (95% CI: 2.803-29.857 months) and 5.570 months (95% CI: 2.441-8.699 months), respectively (chi(2)=8.799, P=0.003).
CONCLUSIONErlotinib monotherapy is safe and effective for some Chinese NSCLC patients after failure of prior chemotherapy.
